Anx-131 [ 360p ]
Watch for Phase 2 readouts in late 2027. If successful, this will be a $5 billion molecule within five years of launch.
If Phase 2 data holds up, ANX-131 could be the first oral drug for anxiety since the invention of the benzodiazepine in the 1950s. ANX-131
But what if there was a third path? Enter , a novel, oral, negative allosteric modulator (NAM) of the GABAA receptor. Watch for Phase 2 readouts in late 2027
